New cancer “vaccine” technology makes progress

According to a report in Medical News Today, researchers at the University of Copenhagen in Denmark have been developing a  new form of immunotherapeutic “vaccine” technology. If it works in cancer in humans at the levels it has worked in treatment of the flu in mice, its potential is considerable … but that’s always a big “if.”

The so-called “InVacc” technology platform consists of a chain of amino acids attached to a gene of the virus which the “patient” needs to be vaccinated against. This genetic cocktail is then inserted into an incapacitated flu-like virus such as an adenovirus and injected into the body, where it triggers a broader and more aggressive immune response, enabling the immune system to quickly seek out and destroy the disease when it invades.

So far, tests of the immunotherapeutic platform on mice have been extremely promising. The Copenhagen group has been able to provide 100 protection of mice against a variety of different, lethal strains of flu given to the test animals. However, the technology has yet to be investigated in man.

According to Jan Pravsgaard, the lead scientist behind the project, “The platform has proved very effective in our recent tests and could have enormous potential. In principle, vaccines of this type could be used to inoculate against a range of deadly viruses, bacteria and other disease-causing agents and even be used to cure certain cancers once they take hold.”

%d bloggers like this: